)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
Hubei Jumpcan Pharmaceutical
Hubei Jumpcan Pharmaceutical (600566) investor relations material
Hubei Jumpcan Pharmaceutical H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary28 Aug, 2026
Executive summary
Revenue for H1 2026 was RMB 2.33 billion, down 15.29% year-over-year; net profit attributable to shareholders rose 8.26% to RMB 784 million.
Gross margin improved as cost controls offset revenue decline; operating cash flow decreased 12.13% year-over-year.
R&D pipeline advanced with new approvals and clinical progress in innovative drugs; key products maintained market leadership.
No interim dividend or capital increase from reserves was proposed.
Financial highlights
Operating income: RMB 2.33 billion (–15.29% YoY); net profit: RMB 784 million (+8.26% YoY).
Gross margin improved as cost of sales fell 28.52% YoY; sales expenses down 22.68%.
Basic and diluted EPS: RMB 0.85 (+8.97% YoY); ROE: 5.33% (+0.42pp YoY).
Net cash from operations: RMB 855 million (–12.13% YoY); total assets: RMB 17.01 billion.
Non-recurring gains: RMB 188 million, mainly from investment and government grants.
Outlook and guidance
Company will continue to invest in R&D and expand product pipeline, focusing on pediatric, respiratory, digestive, and gynecological drugs.
Plans to strengthen digital transformation, supply chain resilience, and multi-channel sales.
Expects ongoing policy and pricing pressures but aims to mitigate via innovation and cost control.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Hubei Jumpcan Pharmaceutical
- 2025 saw revenue and profit drop over 20%, but gross margin and R&D investment remained strong.600566
H2 2025 - Revenue and net profit declined year-over-year, but operating cash flow improved and share buybacks began.600566Q1 2026
- Revenue and profit dropped over 30% year-over-year amid weak demand and lower product sales.600566Q3 2025
- Revenue and profit fell, but core market leadership and high dividend payout were maintained.600566H2 2024
- Q1 2025 saw steep declines in revenue and profit, with a share repurchase plan underway.600566Q1 2025
- Revenue and profit dropped over 30% and 45% respectively, with core products under pressure.600566H1 2025
- Revenue and profit fell year-over-year, with operating cash flow down sharply.600566Q3 2024
- Revenue declined 12.84% in H1 2024, but net profit and R&D investment remained robust.600566H1 2024
Next Hubei Jumpcan Pharmaceutical earnings date
Q3 202623 Oct, 2026
Hubei Jumpcan Pharmaceutical
Next Hubei Jumpcan Pharmaceutical earnings date
Q3 202623 Oct, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage